Arterial hypertension as a sequel to COVID-19. Clinical case report
Journal: Advances in Medicine and Engineering Interdisciplinary Research DOI: 10.32629/ameir.v4i2.5261
Abstract
The COVID-19 disease has caused one of the most important health crises in history. In these terms, this clinical case is reported, which is related to a health worker with no medical history or cardiovascular risk factors. This patient was infected, presenting sequelae of arterial hypertension that required pharmacological treatment. It was showed the need to continue the pathophysiological study of the consequences generated by this pathology, especially regarding arterial hypertension and the potential to establish a critical condition and cardiovascular dysfunction.
Keywords
hypertension; coronavirus infections; complications
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet [Internet]. 2020 [citado 2 Nov 2020]; 395: 470-473. Disponible en: https://www.thelancet.com/action/show Pdf?pii=S0140-6736%2820%2930185-9. https://doi.org/10.1016/ S0140-6736(20)30185-9.
[2] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. CCDC weekly [Internet]. 2020 [citado 4 Nov 2020]; 2(8): 113-122. Disponible en: http://weekly.chin acdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.
[3] World Health Organization. Coronavirus disease (COVID-19) [Internet]. Ginebra: WHO; [actualizado 11 Oct 2020; citado 11 Nov 2020]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/situation -reports/20201012-weekly-epi-update-9.pdf.
[4] Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, Ramos-Rincón JM, Roy-Vallejo E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMICOVID-19 Registry. Rev Clin Esp [Internet]. 2020 [citado 21 Oct 2020]; 220(8): 480–494. Disponible en: https://reader.elsevier.com/reader/sd/pii/S001425652030206X?token=36F2D15E28727572FE2B4871C7593EB13FBA89A58659A67D260FF8B6035E42C3F11CAC371E62E6352DDFC0932738F494.
[5] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on
COVID-19 in China. Clinical Research in Cardiology [Internet]. 2020 [citado 7 Nov 2020]; 109: 531–538. Disponible en: https://link.springer.com/article/10.1007%2Fs00392-020-01626-9. https://doi.org/10.1007/s00392-020-01626-9.
[6] Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. [Internet]. 2021 [citado 1 Ene 2021]; 27(1): 89-95. Disponible en: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30575-9/fulltext.
[7] Silva P, Taborda A, Ahumada L, Fosco MJ, Fundación Favaloro. Asociación entre aislamiento social preventivo obligatorio e hipertensión arterial severa en el servicio de emergencias [Internet]. Buenos Aires: Comunicaciones SAC; 2020 [citado 21 Nov 2020]. Disponible en: https://www.sac.org.ar/trabajos-cientificos/asociacion-entre-aislamiento-social-preventivo-obligatorio-e-hipertension-arterial-severa-en-el-servicio-de-emergencias/.
[8] Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension [Internet]. 2020 [citado 7 Nov 2020]; 75(6): 1334-1357. Disponible en: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15026.
[9] Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertensión y Riesgo Vascular [Internet]. 2020 [citado 10 Nov 2020]; 37(4): 176–180. Disponible en: https://www.sciencedirect.com/science/article/pii/S1889183720300659?via%3Dihub.https://doi.org/10.1016/j.hipert.2020.06.003.
[10] Mandeep RM, Sapan SD, SreyRam K, et al. Cardiovascular Disease, Drug erapy, and Mortality in Covid-19. N Engl J Med [Internet]. 2020 [citado 12 Nov 2020]; 382(25): e102. Disponible en: https://www.nejm.org/doi /pdf/10.1056/NEJMoa2007621?articleTools=true.
[11] Martínez-Pizarro S. Inhibidores del sistema renina-angiotensina en pacientes con COVID-19. Rev. cuba. cardiol. cir. cardiovasc. [Internet]. 2020 Abr [citado 25 Nov 2020]; 26(2): 1-2. Disponible en: http://revcardiologia.sl d.cu/index.php/revcardiologia/article/view/973/pdf.
[12] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Current Cardiology Reports. Springer [Internet] 2020 [citado 6 Nov 2020]; 22(5): 31. Disponible en: https:/ /pubmed.ncbi.nlm.nih.gov/32291526/.
[13] Citro R, Pontone G, Bellino M, et al. Role of multimodality imaging in evaluation of cardiovascular involvement in COVID-19. Trends in Cardiovasc Med [Internet]. 2021 [citado 1 Ene 2021]; 31(1): 17-19. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1050173820301249?via%3Dihub.
[14] Hidalgo P, Villaquirán C, Celis C, García OM, Bermúdez M. Primer informe Grupo Covid Evidencia 110520. Universitas Médica [Internet]. 2020 [citado 16 Nov 2020]; 61(3): 1-6. Disponible en: https://revistas.javerian a.edu.co/index.php/vnimedica/article/view/29781/24214.
[15] Giralt-Herrera A, Rojas-Velázquez JM, Leiva-Enríquez J. Relación entre COVID-19 e Hipertensión Arterial. Rev haban cienc méd [Internet]. 2020 [citado 6 Nov 2020]; 19(2): e_3246. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3246/2493.
[16] López-Ponce de León JD, Cárdenas-Marín PA, Giraldo-González GC, Herrera-Escandón A. Coronavirus –
COVID 19: Más allá de la enfermedad pulmonar, qué es y qué sabemos del vínculo con el sistema cardiovascular. Rev Colomb de Cardiol [Internet]. 2020 [citado 13 Nov 2020]; 27(3): 142-152. Disponible en: https://www.sciencedirect.com/science/article/pii/S0120563320300784?via%3Dihub.
[17] Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res [Internet]. 2020 [citado 8 Nov 2020]; 116(10): 1666-1687. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32352535/.
[18] Pallarés V, Górriz-Zambrano C, Morillas C, et al. COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos? SEMERGEN [Internet]. 2020 [citado 11 Nov 2020]; 46(1): 78-87. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1138359320301441?via%3Dihub.
[19] Choi M, Aiello EA, Ennis IL, Villa-Abrille MC. El SRAA y el SARS-CoV-2: el acertijo a resolver. Hipertensión y Riesgo Vascular [Internet]. 2020 [citado 21 Nov 2020]; 37(4): 169-175. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1889183720300568?via%3Dihub.
[20] Piedra JS, Rodríguez EI, Cuellar CT, García AL. Protocolo de rehabilitación integral para pacientes posinfección
al virus SARS-CoV-2 COVID-19. Rev Cubana de Med Fís y Rehabilit [Internet]. 2020 [citado 17 Nov 2020]; 12(3): 1-22. Disponible en: http://www.revrehabilitacion.sld.cu/index.php/reh/article/view/545/596.
[21] González MA. Bloqueadores del sistema renina-angiotensina: enemigos o amigos en pacientes con COVID-19. Rev Venez de Endocrinol y Metabol [Internet]. 2020 [citado 15 Nov 2020]; 18(1). Disponible en: https://www.redalyc.org/journal/3755/375563116002/html/index.html.
[22] Díaz-Barreiro LA, Cossio-Aranda J, Verdejo-Paris J, Odín-De los Ríos M, Galván-Oseguera H, Álvarez-López H, Alcocer-Gamba MA. COVID-19 y el sistema renina, angiotensina, aldosterona. Una relación compleja. Cardiovasc Metab Sci [Internet]. 2020 [citado 14 Nov 2020]; 31(S3). Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=93945.
[23] Puntmann VO, Carerj L, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 [citado 10 Nov 2020]; 5(11): 1265-1273. Disponible en: https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916.
[2] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. CCDC weekly [Internet]. 2020 [citado 4 Nov 2020]; 2(8): 113-122. Disponible en: http://weekly.chin acdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.
[3] World Health Organization. Coronavirus disease (COVID-19) [Internet]. Ginebra: WHO; [actualizado 11 Oct 2020; citado 11 Nov 2020]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/situation -reports/20201012-weekly-epi-update-9.pdf.
[4] Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, Ramos-Rincón JM, Roy-Vallejo E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMICOVID-19 Registry. Rev Clin Esp [Internet]. 2020 [citado 21 Oct 2020]; 220(8): 480–494. Disponible en: https://reader.elsevier.com/reader/sd/pii/S001425652030206X?token=36F2D15E28727572FE2B4871C7593EB13FBA89A58659A67D260FF8B6035E42C3F11CAC371E62E6352DDFC0932738F494.
[5] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on
COVID-19 in China. Clinical Research in Cardiology [Internet]. 2020 [citado 7 Nov 2020]; 109: 531–538. Disponible en: https://link.springer.com/article/10.1007%2Fs00392-020-01626-9. https://doi.org/10.1007/s00392-020-01626-9.
[6] Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. [Internet]. 2021 [citado 1 Ene 2021]; 27(1): 89-95. Disponible en: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30575-9/fulltext.
[7] Silva P, Taborda A, Ahumada L, Fosco MJ, Fundación Favaloro. Asociación entre aislamiento social preventivo obligatorio e hipertensión arterial severa en el servicio de emergencias [Internet]. Buenos Aires: Comunicaciones SAC; 2020 [citado 21 Nov 2020]. Disponible en: https://www.sac.org.ar/trabajos-cientificos/asociacion-entre-aislamiento-social-preventivo-obligatorio-e-hipertension-arterial-severa-en-el-servicio-de-emergencias/.
[8] Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension [Internet]. 2020 [citado 7 Nov 2020]; 75(6): 1334-1357. Disponible en: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15026.
[9] Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertensión y Riesgo Vascular [Internet]. 2020 [citado 10 Nov 2020]; 37(4): 176–180. Disponible en: https://www.sciencedirect.com/science/article/pii/S1889183720300659?via%3Dihub.https://doi.org/10.1016/j.hipert.2020.06.003.
[10] Mandeep RM, Sapan SD, SreyRam K, et al. Cardiovascular Disease, Drug erapy, and Mortality in Covid-19. N Engl J Med [Internet]. 2020 [citado 12 Nov 2020]; 382(25): e102. Disponible en: https://www.nejm.org/doi /pdf/10.1056/NEJMoa2007621?articleTools=true.
[11] Martínez-Pizarro S. Inhibidores del sistema renina-angiotensina en pacientes con COVID-19. Rev. cuba. cardiol. cir. cardiovasc. [Internet]. 2020 Abr [citado 25 Nov 2020]; 26(2): 1-2. Disponible en: http://revcardiologia.sl d.cu/index.php/revcardiologia/article/view/973/pdf.
[12] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Current Cardiology Reports. Springer [Internet] 2020 [citado 6 Nov 2020]; 22(5): 31. Disponible en: https:/ /pubmed.ncbi.nlm.nih.gov/32291526/.
[13] Citro R, Pontone G, Bellino M, et al. Role of multimodality imaging in evaluation of cardiovascular involvement in COVID-19. Trends in Cardiovasc Med [Internet]. 2021 [citado 1 Ene 2021]; 31(1): 17-19. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1050173820301249?via%3Dihub.
[14] Hidalgo P, Villaquirán C, Celis C, García OM, Bermúdez M. Primer informe Grupo Covid Evidencia 110520. Universitas Médica [Internet]. 2020 [citado 16 Nov 2020]; 61(3): 1-6. Disponible en: https://revistas.javerian a.edu.co/index.php/vnimedica/article/view/29781/24214.
[15] Giralt-Herrera A, Rojas-Velázquez JM, Leiva-Enríquez J. Relación entre COVID-19 e Hipertensión Arterial. Rev haban cienc méd [Internet]. 2020 [citado 6 Nov 2020]; 19(2): e_3246. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3246/2493.
[16] López-Ponce de León JD, Cárdenas-Marín PA, Giraldo-González GC, Herrera-Escandón A. Coronavirus –
COVID 19: Más allá de la enfermedad pulmonar, qué es y qué sabemos del vínculo con el sistema cardiovascular. Rev Colomb de Cardiol [Internet]. 2020 [citado 13 Nov 2020]; 27(3): 142-152. Disponible en: https://www.sciencedirect.com/science/article/pii/S0120563320300784?via%3Dihub.
[17] Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res [Internet]. 2020 [citado 8 Nov 2020]; 116(10): 1666-1687. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32352535/.
[18] Pallarés V, Górriz-Zambrano C, Morillas C, et al. COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos? SEMERGEN [Internet]. 2020 [citado 11 Nov 2020]; 46(1): 78-87. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1138359320301441?via%3Dihub.
[19] Choi M, Aiello EA, Ennis IL, Villa-Abrille MC. El SRAA y el SARS-CoV-2: el acertijo a resolver. Hipertensión y Riesgo Vascular [Internet]. 2020 [citado 21 Nov 2020]; 37(4): 169-175. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1889183720300568?via%3Dihub.
[20] Piedra JS, Rodríguez EI, Cuellar CT, García AL. Protocolo de rehabilitación integral para pacientes posinfección
al virus SARS-CoV-2 COVID-19. Rev Cubana de Med Fís y Rehabilit [Internet]. 2020 [citado 17 Nov 2020]; 12(3): 1-22. Disponible en: http://www.revrehabilitacion.sld.cu/index.php/reh/article/view/545/596.
[21] González MA. Bloqueadores del sistema renina-angiotensina: enemigos o amigos en pacientes con COVID-19. Rev Venez de Endocrinol y Metabol [Internet]. 2020 [citado 15 Nov 2020]; 18(1). Disponible en: https://www.redalyc.org/journal/3755/375563116002/html/index.html.
[22] Díaz-Barreiro LA, Cossio-Aranda J, Verdejo-Paris J, Odín-De los Ríos M, Galván-Oseguera H, Álvarez-López H, Alcocer-Gamba MA. COVID-19 y el sistema renina, angiotensina, aldosterona. Una relación compleja. Cardiovasc Metab Sci [Internet]. 2020 [citado 14 Nov 2020]; 31(S3). Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=93945.
[23] Puntmann VO, Carerj L, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 [citado 10 Nov 2020]; 5(11): 1265-1273. Disponible en: https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916.
Copyright © 2026 Fausto Vinicio Maldonado Coronel, Diana Karina Haro Medina, Bryan Jesús Morales Fiallos, Katherine Paulina Maldonado Coronel, Darwin Patricio Yaucén Yumi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License